NCT04915417View on ClinicalTrials.gov

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma

NAUnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2024

Conditions
Resectable Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Interventions
RADIATION

Stereotactic Ablative Body Radiotherapy (SABR)

Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.

Sponsors
All Listed Sponsors
collaborator

London Health Sciences Foundation

UNKNOWN

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER